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age at diagnosis is 7.04 (range 2–14). 22.7% of the
ADHD-children exhibit a score below 15 on the IOWA-
CRS, 54.06% have a score between 15 and 22 and 22.7%
suffers from a severe form of ADHD with a score above
22 (maximum 30). The resource use of an ADHD-child
is signiﬁcantly higher compared to their siblings. Using
McNemar tests we found that ADHD-children are sig-
niﬁcantly more likely to have emergency department visits
(20.4% vs. 6.8%) and specialist visits (22% vs. 3.2%).
The severity of the disorder is positively related to med-
ication and specialist use (Wilcoxon Signed Rank Test).
Parents stay signiﬁcantly more often home from work 
for their ADHD-child (10.6% vs 2.4%) and signiﬁcantly
more children with ADHD miss a year at school (17.2%
vs. 4.3%) or go to a special school for children with learn-
ing disabilities (10% vs. 0.9%). CONCLUSION: Child-
hood ADHD results in signiﬁcantly higher use of health
care and adversely affects school attainments and parents’
productivity. This puts a heavy burden on the family.
Nevertheless we have to take into consideration we have
used a non-random sample and that we used siblings as
a comparator group.
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OBJECTIVE: The CURE trial demonstrated the superior
efﬁcacy of clopidogrel compared to placebo, both groups
receiving standard therapy including ASA in prevent-
ing myocardial infarctions, strokes, and cardiovascular
deaths in patients with ACS. The purpose of this analy-
sis was to evaluate short and long term cost-effectiveness
of clopidogrel in 4 Scandinavian countries: Denmark,
Finland, Norway and Sweden. METHODS: A within
trial analysis was performed based on data collected
alongside the clinical trial (hospitalizations, procedures,
comedications, and study drugs). Hospitalizations costs
were evaluated through a Diagnosis Related Group
approach. Cost-effectiveness was expressed as the cost
per event avoided. A long term model using Swedish epi-
demiological data (national registry) was also performed
to capture the long term beneﬁts of clopidogrel. A
Markov model with six states (at risk, ﬁrst year with
stroke, following years with stroke, ﬁrst year with new
MI, following years with new MI and death) was used.
Cost-effectiveness was expressed as the cost per life year
gained (LYG). Costs used were for the 2001 year. Both
costs and beneﬁts were discounted at 3%. RESULTS:
Occurrence of the composite outcome was signiﬁcantly
lower in the clopidogrel arm (11.14% versus 13.15%).
Patients in the clopidogrel arm have on average higher
costs than patients treated with ASA alone: the net incre-
mental cost ranges from €289 to €488. This leads to a
cost per event avoided ranging from €13,391 to €24,700.
The long term model predicts an incremental survival of
0.117 years for an incremental direct medical cost ranging
from €64 to €488 per patient. The cost per LYG ranges
from €549 to €4003. When indirect costs are included this
ratio is €2181 in Finland and clopidogrel is cost saving
in other countries. CONCLUSION: Both short and long
term analyses conclude that clopidogrel is very cost effec-
tive in the treatment of patients with ACS.
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OBJECTIVES: To determine the incremental cost per life
year saved (ICLYS) of clopidogrel versus ASA in sec-
ondary prevention of ischemic stroke (IS), myocardial
infarction (MI), or vascular death (VD) in 2 high risk sub-
groups of the CAPRIE trial (patients with prior IS or MI
to index event, and atherothrombotic patients treated for
hypercholesterolemia and/or with diabetes) in Belgium.
METHODS: A Markov model designed with 7 clinical
states calculated ICLYS as the cost needed to achieve an
extra life year with clopidogrel compared to ASA. The
model combined rates of clinical outcomes calculated
from the CAPRIE database and survival data derived
from the Saskatchewan database. The costing of events,
including acute care and follow-up, was performed using
ofﬁcial data (DRG systems), tariffs and/or charges (physi-
cians fees, examinations, lab tests), divided in acute costs
and costs per subsequent 6 month follow-up periods. The
economic analysis was performed from the health care
system perspective using only direct medical costs for 
2-year treatment. A discount rate of 3% was applied to
costs and lifetime effects. RESULTS: In ﬁrst subgroup
(prior MI or IS), 27 additional atherothrombotic events
(14 MI, 12 IS, 1VD) were avoided per 1000 patients
treated with clopidogrel versus ASA with a gain in 
survival of 119 years. In second subgroup (hypercholes-
terolemia and/or diabetes), 28 additional atherothrom-
botic events (14 MI, 8 IS, 6VD) were avoided with a gain
in survival of 130 years per 1000 patients. The incre-
mental cost of the clopidogrel arm compared to ASA was
€702 in ﬁrst group and €771 in second group. The ICLYS
was very similar in the 2 subgroups: €5900 and €5930
respectively. Results were robust under a wide variation
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of key parameters. CONCLUSION: Clopidogrel as an
alternative to ASA is a cost-effective strategy in secondary
prevention of ischemic events for high-risk atherothrom-
botic patients.
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OBJECTIVES: Fondaparinux, a new synthetic selective
factor XA inhibitor was recently introduced into the
market. This may have widespread implications for
Health care providers that are expected to vary across
countries. We evaluated the cost-effectiveness of fonda-
parinux relative to enoxaparin up to 5-years in the pre-
vention of venous thromboembolism (VTE) following
major orthopaedic surgery and compared the results
across European countries. METHODS: We developed
an economic model and assessed the effect of fonda-
parinux relative to enoxaparin , both given for 7 days, on
patient clinical outcomes and costs in Belgium, Italy, The
Netherlands, Spain, UK. The perspective was that of 
the third party payer. Outcomes are symptomatic deep
vein thrombosis, pulmonary embolism, recurrences, post-
thrombotic syndrome and death. Data on the incidence
of VTE events were derived from four randomised clini-
cal trials comparing enoxaparin with fondaparinux, and
from a review of the literature. Resource consequences
and costs were estimated locally using national or hospi-
tal databases, clinician opinion, literature . . . and vali-
dated by experts. RESULTS: In a hypothetical cohort 
of 1000 patients, weighted to reﬂect the proportion of
patients undergoing hip or knee replacement, or hip frac-
ture surgery in each country, the expected number of VTE
events averted with fondaparinux ranged from 17 to 20
and the number of VTE-related deaths averted is 2 to 3.
Results were consistent across countries: break-even point
in costs was achieved at day 90 or even earlier. The
expected savings with fondaparinux at 5 years would
range between €26,000 and €38,000. These ﬁndings were
found to be robust to wide variations in key assumptions
in the model. CONCLUSIONS: Compared with current
practice in Europe, fondaparinux is a cost-effective and
dominant strategy in the prophylaxis of venous throm-
boembolism following major orthopaedic surgery in all
countries investigated.
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Drug-eluting stents (DES) have been shown to reduce the
risk of restenosis post coronary intervention compared
with conventional stents (CS). However, the cost of DES
is signiﬁcantly higher than CS. OBJECTIVE: To evaluate
the utilization of DES along with clinical indications, out-
comes and cost impact within the cardiac catheterization
lab. METHODS: Demographic, clinical and angiographic
data were collected retrospectively on all patients who
underwent DES implantation between October 15, 2002
and April 15, 2003. Cost data, speciﬁcally stent costs,
were collected concurrently. RESULTS: A cohort of 46
patients was treated with DES, involving 52 vessels and
utilizing 62 stents (56 Cypher, 6 Taxus). Indications for
coronary intervention were stable angina (67.2%) and
ACS/post MI (32.6%). Indications for DES use included
clinical reasons such as diabetes mellitus (15.2%), prior
bypass surgery (19.6%) and renal insufﬁciency (8.7%).
Angiographic indications included: stenosis length 
>18mm (43.4%), vessel diameter <2.5mm (32.6%),
patients with multivessel disease (21.7%) and instent
restenosis (8.7%). Short-term clinical complications
included death but no strokes or myocardial infarctions.
The procedural success was 95.8% (44/46), and the clin-
ical success was 92.5% (43/46). The average number of
DES per patient was 1.35. During the same time period,
351 patients were treated with CS, utilizing 522 stents.
The average number of stents per patient was 1.48. The
total hospital-incurred DES cost was $227,500 for an
average stent cost $4945.65 per patient. In the CS group
the total cost for stents was $496,050 for an average cost
of $1413.25 per patient. The average stent cost per
patient was 3.5 times higher in the DES group than with
CS. CONCLUSIONS: 1) Indications for DES use are con-
sistent with individuals at higher risk for restenosis; 2) the
procedural costs for treating these individuals are signif-
icantly greater; and 3) full 6 month outcomes and cost
data will be available for presentation.
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